Credits: Canva
The clothes you wear when you work out may do you more harm than helping you to stay healthy as you hit the gym. This is because research has revealed alarming levels of bisphenol A (BPA), a chemical compound linked to significant health risks in several sports wear, including sports bra, leggings, and athletic wear. The Center for Environmental Health (CEH), which is a nonprofit consumer advocacy group has brought these concerns to light, and have raised awareness about the potential danger and damage these sports wear can cause because of the common chemicals used.
Bisphenol A, or BPA is a chemical that is used to make plastics and resins. It is also used in certain fabrics and is known for its endocrine-disrupting properties, which can also interfere with one's hormonal balance. There have been studies, including a 2019 study titled The adverse health effects of bisphenol A and related toxicity mechanisms that have linked BPA exposure to various health problems, including asthma, cardiovascular diseases, obesity, diabetes, and even cancer.
Many of research which have been conducted focus on the ingestion, which can happen when you store food in BPA-lined containers. Among them, some of the more recent studies show that skin absorption is also a pathway. This means when you are handling receipts which are printed on thermal paper, or wear BPA-containing fabrics, the chemical can seep through your skin and enter your bloodstream.
Though it is also true that BPA is exposed from the body within days, however, continuous exposure from multiple sources can be concerning.
CEH also tested popular athletic wear in October 2023 and found BPA levels were exceeding California's safety standards by as much as 22 times.
Testing also showed that top brands contained up to 40 times the permissible limit of BPA.
As far as laws are concerned, under California's Proposition 65, the maximum allowable dose for BPA exposure via skin is 3 micrograms per day. While this law is among the strictest in the United States, it highlights a broader issue of chemical safety in consumer products nationwide.
Ana Soto, an immunologist with decades of research on BPA, even low doses of dermal and oral exposure can combine to create a significant health risk. She also warned that prolonged exposure through fabric, especially when you are exercising, as your pores are open and sweat is present, can in fact, amplify these effects.
BPA can disrupt your body's endocrine system, which is a network of glands and organs that produce hormones that control many bodily functions. These include growth and development, metabolism, and reproduction, to name a few. BPA can mimic natural hormones like estrogen and interfere in those bodily functions.
Studies also link it with obesity and diabetes, respiratory issues, especially asthma risk in school-aged children, cardiovascular diseases, and cancer risks.
There are certain steps you can follow to protect yourself:
Credit: AI
As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to help manage metabolic disorders and obesity, a new trend is rapidly gaining traction on social media - GLP-1 microdosing.
Instead of taking the prescribed doses approved for diabetes or obesity, some users are deliberately taking much smaller amounts, claiming they can lose weight, reduce food noise, avoid side effects, save money, or even improve longevity.
However, experts warn that there is currently little scientific evidence that GLP-1 microdosing is safe or even effective.
Some people reduce their dose by extending the time between injections, counting "clicks" on injection pens instead of using prescribed doses, or taking customized low-dose formulations.
HealthandMe spoke to Dr. Shehla Shaikh, Consultant Endocrinologist, Saifee Hospital, Mumbai, about the trend of GLP-1 microdosing.
Dr. Shaikh says, "The lowest dose that is supported by evidence for semaglutide is 0 25 mg. While, for tirzepatide, it is 2 5 mg Some people are using much smaller amounts for example using nine clicks on a semaglutide pen which gives about 0 06 mg. Now there are no randomized studies or clear guidelines that show if this kind of micro-dosing is safe or works."
Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real
Medical experts caution that these practices fall outside approved prescribing guidelines and have not been rigorously studied.
The expert says, "One big worry is how accurate the dose is. These injectable pens are made to give set approved amounts; not amounts based on people counting clicks. Even a small mistake in counting can mean taking too little medicine which may not work well or too much, which could cause more problems. Since these instructions are complicated, they need careful handling good eyesight and understanding of the device."
These medications are expensive in various countries. So, people stretch a single prescription by taking less medication than prescribed.
Rather than pursuing significant weight loss, some users say they simply want to maintain previous results or reduce constant food cravings without taking full doses.
Online influencers have begun promoting low-dose GLP-1s as potential "longevity drugs." While GLP-1 medications show promise for heart and metabolic health, experts stress that these benefits have only been demonstrated using clinically tested doses, not microdoses.
Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?
Taking too little medication may fail to adequately suppress appetite, improve blood sugar levels, or achieve meaningful weight loss.
Dr. Shaikh says, "People often choose microdosing because they want to avoid problems reduce appetite with a smaller dose or make a costly medicine last longer. While smaller amounts might help a bit, current information shows that the best and steadiest results come from following the approved ways to take the medicine. Using doses that are too low might not give the results to people who want to lose weight or manage their metabolic health."
Experts also say that people with obesity or diabetes could unknowingly receive suboptimal treatment while believing they are protected. Another problem is how long the medicine lasts after it is opened.
Dr. Shaikh explains, "An opened semaglutide pen should be used within 60 days while an opened tirzepatide pen should be used within 30 days. Because microdosing uses the medicine over a longer time, people might keep using it past the time it is safe which could change how good it is."
Also read: Could GLP-1 Weight Loss Drugs Help People Take Fewer Sick Days? New Study Says So
Some users manually estimate doses by counting injection pen clicks. Experts warn these devices are designed to deliver specific calibrated doses, making partial dosing unreliable.
The expert says, "Some people think micro-dosing gives similar benefits with fewer problems or lower costs, but this practice has no scientific support and might have several dangers."
Credit: iStock
A Doppler test is a specialized type of ultrasound that uses sound waves to measure blood flow through blood vessels rather than simply creating images of organs and tissues. Unlike a regular ultrasound, which produces pictures of internal structures, a Doppler ultrasound shows how blood moves through arteries and veins, helping doctors detect circulation problems.
While commonly associated with pregnancy, Doppler ultrasound is also used to investigate conditions such as leg pain, swelling, varicose veins, blood clots, peripheral artery disease, and stroke risk. Understanding when this test is needed can help detect serious conditions early and guide timely treatment.
During pregnancy, a Doppler ultrasound is often recommended in high-risk cases to assess blood flow between the mother, placenta, and baby.
"It helps doctors monitor whether the fetus is receiving adequate oxygen and nutrients, making it especially important in pregnancies complicated by high blood pressure, diabetes, fetal growth restriction, or previous pregnancy-related complications," Dr. Vandana Mittal, Principal Consultant, Obstetrics and Gynecology, Paras Health Panchkula, told HealthandMe.
Dr. Vandana Jain, Principal Consultant - Obstetrics, Gynecology, Infertility & Advanced Laparoscopic Surgery, Yashoda Medicity, added that the test is commonly recommended in high-risk pregnancies, including fetal growth restriction, preeclampsia, hypertension, gestational diabetes, oligohydramnios, multiple pregnancies, and decreased fetal movements.
"By evaluating how effectively oxygen and nutrients are reaching the baby, the test helps detect signs of fetal compromise at an early stage, enabling timely monitoring, appropriate medical intervention, and informed decisions regarding the timing and mode of delivery."
By identifying potential issues early, Doppler studies help doctors monitor pregnancies more closely and intervene when necessary. However, the test is performed only for specific medical indications and is not a replacement for routine pregnancy ultrasounds.
According to the Mayo Clinic, a Doppler ultrasound can help diagnose:
How Doppler Ultrasound Can Help People With Leg Pain
Dr. Jain said Doppler ultrasound is also commonly advised for patients with suspected Deep Vein Thrombosis (DVT), peripheral arterial disease, carotid artery narrowing, or chronic venous insufficiency.
"It is commonly advised for patients with suspected Deep Vein Thrombosis (DVT), peripheral arterial disease, carotid artery narrowing, or chronic venous insufficiency," she told HealthandMe.
The expert added that people with persistent leg pain while walking, unexplained swelling, non-healing wounds, or symptoms of poor circulation may require a Doppler evaluation.
Recently, gastroenterologist Dr. Pal Manickam highlighted the importance of Doppler ultrasound during a podcast discussion. He urged people not to ignore sudden leg pain or swelling, noting that these symptoms could indicate deep vein thrombosis (DVT) and require prompt evaluation.
The procedure is painless, non-invasive, and usually takes 30 to 60 minutes, depending on the area being examined. It is also radiation-free.
A Doppler ultrasound is performed by a trained sonographer using a hand-held device called a transducer. The transducer sends sound waves into the body and measures how they bounce off moving blood cells, allowing the machine to assess blood flow in real time.
Credit: iStock
A new high-precision radiotherapy treatment introduced by NHS England is set to offer a faster and more convenient treatment option for thousands of men with prostate cancer.
Known as stereotactic ablative radiotherapy (SABR), the treatment delivers high-dose radiation in just five sessions over two weeks, compared with the 20 or more sessions typically required with conventional radiotherapy. This means eligible patients can complete treatment with 15 fewer hospital visits, reducing the burden of travel and time spent in care.
Prostate cancer is the most common cancer among men in the UK. More than 55,000 men are diagnosed with the disease each year, while around 12,300 die from it annually.
According to NHS Chief Executive Sir Jim Mackey, the new therapy will "transform" treatment for thousands of men with localized prostate cancer while enabling the NHS to provide "far more powerful and more convenient" cancer care.
According to NHS England, stereotactic ablative radiotherapy (SABR) delivers highly targeted radiation to the tumor from multiple angles, helping reduce the risk of the cancer returning or spreading.
The treatment delivers a higher dose of radiation with pinpoint accuracy, minimizing damage to surrounding healthy tissue and reducing the likelihood of side effects.
"This technology lets us focus a powerful and precise beam of radiotherapy directly onto the cancer, limiting the damage to healthy cells – and the fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly," said Professor Peter Johnson, NHS National Clinical Director for Cancer.
Also known as stereotactic body radiotherapy (SBRT), SABR is already used to treat certain lung and brain cancers. It is now being offered on the NHS to eligible men with low- and intermediate-risk localized prostate cancer.
Around 17,500 men in England are diagnosed with low- or intermediate-risk prostate cancer each year and could be eligible for SABR.
NHS modeling suggests that nearly one in five of these patients—around 3,500 men annually—may choose the treatment to help reduce the risk of their cancer spreading.
The treatment is expected to be available across all 48 NHS radiotherapy centers in England, with the first hospitals beginning to offer it from next week.
The NHS estimates that introducing SABR for prostate cancer could free up around 50,000 treatment appointments each year.
By shortening treatment schedules and reducing the number of hospital visits, the rollout is expected to improve capacity across radiotherapy services while helping bring down waiting times for cancer patients.
However, SABR is not suitable for everyone with localized prostate cancer. Experts advise patients to discuss their treatment options with their specialist team, while ongoing research continues to evaluate the therapy in different patient groups.
Read More: Over 40% Prostate Cancer Patients in India Diagnosed After Cancer Has Spread: ICMR study
The prostate is a small, walnut-shaped gland in men that produces seminal fluid, which nourishes and transports sperm. Prostate cancer develops when abnormal cells begin to grow uncontrollably in the gland.
Experts say not all prostate cancers are life-threatening. Many are slow-growing and may never affect a man's lifespan. In fact, such cancers are found in around one in three men over the age of 50. However, a smaller number of prostate cancers are aggressive, spread quickly, and require prompt treatment, making early detection and regular screening important.
Early-stage prostate cancer may cause:
More advanced prostate cancer may lead to:
© 2024 Bennett, Coleman & Company Limited